Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.

Lim WH, Eris J, Kanellis J, Pussell B, Wiid Z, Witcombe D, Russ GR.

Am J Transplant. 2014 Sep;14(9):2106-19. doi: 10.1111/ajt.12795. Epub 2014 Aug 1. Review.

2.

Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.

Glover TE, Watson CJ, Gibbs P, Bradley JA, Ntzani EE, Kosmoliaptsis V.

Transplantation. 2016 Mar;100(3):621-9. doi: 10.1097/TP.0000000000001006. Review.

PMID:
26636736
3.

Conversion From Calcineurin Inhibitors to Mammalian Target-of-Rapamycin Inhibitors in Heart Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials.

Qiu Y, Wang X, Fan J, Rao Z, Lu Y, Lin T.

Transplant Proc. 2015 Dec;47(10):2952-6. doi: 10.1016/j.transproceed.2015.09.059. Review.

PMID:
26707320
4.

Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.

Yan HL, Zong HT, Cui YS, Li N, Zhang Y.

Transplant Proc. 2014 Jun;46(5):1302-13. doi: 10.1016/j.transproceed.2014.02.010.

PMID:
24935293
5.

Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.

Su L, Tam N, Deng R, Chen P, Li H, Wu L.

Int Urol Nephrol. 2014 Oct;46(10):2035-44. doi: 10.1007/s11255-014-0783-1. Epub 2014 Jul 16. Review.

PMID:
25027805
7.

Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.

Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ; ASCERTAIN Investigators.

Transplantation. 2011 Aug 27;92(4):410-8. doi: 10.1097/TP.0b013e318224c12d. Erratum in: Transplantation. 2011 Nov 27;92(10):e61. multiple investigator names added..

PMID:
21697773
8.

Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation.

de Paula MI, Medina Pestana JO, Nicolau Ferreira A, Pontello Cristelli M, Fabiano Franco M, Aguiar WF, Tedesco-Silva H, Rosso Felipe C.

Ther Drug Monit. 2016 Feb;38(1):22-31. doi: 10.1097/FTD.0000000000000227.

PMID:
26121616
9.

Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.

Cervera C, Cofan F, Hernandez C, Soy D, Marcos MA, Sanclemente G, Bodro M, Moreno A, Diekmann F, Campistol JM, Oppenheimer F.

Transpl Int. 2016 Nov;29(11):1216-1225. doi: 10.1111/tri.12848. Epub 2016 Sep 26.

PMID:
27564469
10.

Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.

Hüsing A, Schmidt M, Beckebaum S, Cicinnati VR, Koch R, Thölking G, Stella J, Heinzow H, Schmidt HH, Kabar I.

Ann Transplant. 2015 Nov 26;20:707-13.

11.

Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis.

Murakami N, Riella LV, Funakoshi T.

Am J Transplant. 2014 Oct;14(10):2317-27. doi: 10.1111/ajt.12852. Epub 2014 Aug 21. Review.

12.

Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.

Kamar N, Del Bello A, Belliere J, Rostaing L.

Transpl Int. 2015 Aug;28(8):928-37. doi: 10.1111/tri.12515. Epub 2015 Jan 29. Review.

13.

Experience with belatacept rescue therapy in kidney transplant recipients.

Brakemeier S, Kannenkeril D, Dürr M, Braun T, Bachmann F, Schmidt D, Wiesener M, Budde K.

Transpl Int. 2016 Nov;29(11):1184-1195. doi: 10.1111/tri.12822. Epub 2016 Sep 14.

PMID:
27514317
14.

Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.

Helal I, Chan L.

Transplant Proc. 2011 Mar;43(2):472-7. doi: 10.1016/j.transproceed.2011.01.054. Review.

PMID:
21440737
15.

Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.

Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P.

Transpl Int. 2014 Oct;27(10):1039-49. doi: 10.1111/tri.12372. Epub 2014 Jul 18. Review.

16.

Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.

Webster AC, Lee VW, Chapman JR, Craig JC.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004290. Review.

PMID:
16625599
17.

Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis.

Moore J, Middleton L, Cockwell P, Adu D, Ball S, Little MA, Ready A, Wheatley K, Borrows R.

Transplantation. 2009 Feb 27;87(4):591-605. doi: 10.1097/TP.0b013e318195a421. Review.

PMID:
19307799
18.

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F; ZEUS Study Investigators.

Lancet. 2011 Mar 5;377(9768):837-47. doi: 10.1016/S0140-6736(10)62318-5. Epub 2011 Feb 19. Erratum in: Lancet. 2012 Dec 8;380(9858):1994. Lancet. 2011 Jun 11;377(9782):2006. Wüthrich, Rudolf P [added].

PMID:
21334736
19.

Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.

Sert M, Celik A, Kural K, Ersan S, Ataca P, Atila K, Cavdar C, Sifil A, Bora S, Gulay H, Camsari T.

Ren Fail. 2011;33(8):789-94. doi: 10.3109/0886022X.2011.601826. Epub 2011 Jul 25.

PMID:
21787153
20.

Treatment with everolimus is associated with a procoagulant state.

Baas MC, Gerdes VE, Ten Berge IJ, Heutinck KM, Florquin S, Meijers JC, Bemelman FJ.

Thromb Res. 2013 Aug;132(2):307-11. doi: 10.1016/j.thromres.2013.07.004. Epub 2013 Jul 29.

PMID:
23906938

Supplemental Content

Support Center